Indeed, the approval of beta interferon (IFN-β) drugs in the 1990s as the first disease-modifying therapy (DMT) for RRMS accelerated MS research towards immunomodulatory approaches by demonstrating the efficacy of cytokine regulation and, as it was later elucidated, alteration of T cell subpopulations [11–14]. The gene discussed is IFNB1; the disease is myeloid sarcoma.